Hib conjugate vaccine - Chengdu Olymvax BiopharmaceuticalsAlternative Names: Haemophilus influenzae type b conjugate vaccine - Chengdu Olymvax Biopharmaceuticals
Latest Information Update: 03 Mar 2016
At a glance
- Originator Chengdu Olymvax Biopharmaceuticals
- Developer Chengdu Olymvax Biopharmaceuticals; Jiangsu Provincial Center for Disease Control and Prevention
- Class Haemophilus vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Haemophilus infections